Alliance Global Partners analyst James Molloy initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $35 price target vTv is a clinical-stage pharmaceutical company focused on developing treatment options for metabolic and inflammatory diseases, primarily targeting type 1 diabetes, the analyst tells investors in a research note. The firm says cadisegliatin’s mechanism of action allows for liver function restoration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT: